Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease

References

• Aquino CC , Fox SH . Clinical spectrum of levodopa-induced complications. Mov Disord 2015;30(1):80-9
   PubMed Web of Science ®Google Scholar
• Olanow CW , Watts RL , Koller WC . An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001;56(11 Suppl 5):S1-S88
   PubMed Web of Science ®Google Scholar
• Pahwa R , Factor SA , Lyons KE , et al. Practice parameter: treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). report of the quality standards subcommittee of the american academy of neurology. Neurology 2006;66(7):983-95
   PubMed Web of Science ®Google Scholar
• Stacy M , Bowron A , Guttman M , et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20(6):726-33
   PubMed Web of Science ®Google Scholar
• Stocchi F . The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006;7(10):1399-407
   PubMedGoogle Scholar
• Martinez-Martin P , Tolosa E , Hernandez B , Badia X . The patient card questionnaire to identify wearing-off in parkinson disease. Clin Neuropharmacol 2007;30(5):266-75
   PubMed Web of Science ®Google Scholar
• Pahwa R , Lyons KE . Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin 2009;25(4):841-9
   PubMed Web of Science ®Google Scholar
• Antonini A , Martinez-Martin P , Chaudhuri RK , et al. Wearing-off scales in Parkinson’s disease: Critique and recommendations. Mov Disord 2011;26(12):2169-75
   PubMed Web of Science ®Google Scholar
• Fox SH , Katzenschlager R , Lim SY , et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Ferreira JJ , Katzenschlager R , Bloem BR , et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 2013;20(1):5-15
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE) Clinical Guideline CG35. . Parkinson’s disease: diagnosis and management in primary and secondary care 2006.
   Google Scholar
• Grimes D , Gordon J , Snelgrove B , et al. Canadian Guidelines on Parkinson’s Disease. Can J Neurol Sci 2012;39(4 Suppl 4):S1-30
   PubMed Web of Science ®Google Scholar
• Wu H , Dong F , Wang Y , et al. Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson’s disease. Parkinsonism Relat Disord 2014;20(10):1094-6
   PubMed Web of Science ®Google Scholar
• Yoritaka A , Hattori N , Yoshino H , Mizuno Y . Catechol-O-methyltransferase genotype and susceptibility to Parkinson’s disease in Japan. Short communication. J Neural Transm 1997;104(11-12):1313-17
   PubMed Web of Science ®Google Scholar
• Hao H , Shao M , An J , et al. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson’s disease in a Chinese population. Parkinsonism Relat Disord 2014;20(10):1041-5
   PubMed Web of Science ®Google Scholar
• Hulihan MM , Ishihara-Paul L , Kachergus J , et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008;7(7):591-4
   PubMed Web of Science ®Google Scholar
• Nabli F , Ben Sassi S , Amouri R , et al. Motor phenotype of LRRK2-associated Parkinson’s disease: a Tunisian longitudinal study. Mov Disord 2015;30(2):253-8
   PubMed Web of Science ®Google Scholar
• Lucking CB , Abbas N , Durr A , et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson’s Disease and the French Parkinson’s Disease Genetics Study Group. Lancet 1998;352(9137):1355-6
   PubMed Web of Science ®Google Scholar
• Hauser RA , McDermott MP , Messing S . Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63(12):1756-60
   PubMed Web of Science ®Google Scholar
• Olanow CW , Kieburtz K , Rascol O , et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013;28(8):1064-71
   PubMed Web of Science ®Google Scholar
• Stocchi F , Jenner P , Obeso JA . When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease? Eur Neurol 2010;63(5):257-66
   PubMed Web of Science ®Google Scholar
• Cilia R , Akpalu A , Sarfo FS , et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 2014;137(Pt 10):2731-42
   PubMed Web of Science ®Google Scholar
• Yoritaka A , Shimo Y , Takanashi M , et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: prevalence and risks. Parkinsonism Relat Disord 2013;19(8):725-31
   PubMed Web of Science ®Google Scholar
• Sato K , Hatano T , Yamashiro K , et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006;21(9):1384-95
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ , Del Val J , Fernandez IM , Herranz A . What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol 2012;35(1):1-5
   PubMed Web of Science ®Google Scholar
• Wickremaratchi MM , Knipe MD , Sastry BS , et al. The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord 2011;26(3):457-63
   PubMed Web of Science ®Google Scholar
• Kostic V , Przedborski S , Flaster E , Sternic N . Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 1991;41(2(Pt 1)):202-5
   PubMed Web of Science ®Google Scholar
• Martinelli P , Contin M , Scaglione C , et al. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 2003;24(3):192-3
   PubMed Web of Science ®Google Scholar
• Ahlskog JE , Muenter MD . Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-58
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000;284(15):1931-8
   PubMed Web of Science ®Google Scholar
• Hattori N , Fujimoto K , Kondo T , et al. Patient perspectives on Parkinson’s disease therapy in Japan and the United States: results of two patient surveys. Patient Relat Outcome Meas 2012;3:31-8
   PubMedGoogle Scholar
• Lechun L , Yu S , Pengling H , Changqi H . The COMT Val158Met polymorphism as an associated risk factor for Parkinson’s disease in Asian rather than Caucasian populations. Neurol India 2013;61(1):12-16
   PubMed Web of Science ®Google Scholar
• Chuan L , Gao J , Lei Y , et al. Val158Met polymorphism of COMT gene and Parkinson’s disease risk in Asians. Neurol Sci 2015;36(1):109-15
   PubMed Web of Science ®Google Scholar
• Kum WF , Gao J , Durairajan SS , et al. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson’s disease. J Clin Neurosci 2009;16(8):1034-7
   PubMed Web of Science ®Google Scholar
• Chen W , Xiao Q , Shao M , et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener 2014;3(1):26
   PubMedGoogle Scholar
• Seki M , Takahashi K , Uematsu D , et al. Clinical features and varieties of non-motor fluctuations in Parkinson’s disease: a Japanese multicenter study. Parkinsonism Relat Disord 2013;19(1):104-8
   PubMed Web of Science ®Google Scholar
• Kulkantrakorn K , Tiamkao S , Pongchaiyakul C , Pulkes T . Levodopa induced motor complications in Thai Parkinson’s disease patients. J Med Assoc Thai 2006;89(5):632-7
   PubMedGoogle Scholar
• Stacy M , Hauser R , Oertel W , et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006;29(6):312-21
   PubMed Web of Science ®Google Scholar
• Witjas T , Kaphan E , Azulay JP , et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002;59(3):408-13
   PubMed Web of Science ®Google Scholar
• Shulman LM , Taback RL , Rabinstein AA , Weiner WJ . Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002;8(3):193-7
   PubMed Web of Science ®Google Scholar
• Bares M , Rektorova I , Jech R , et al. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? J Neural Transm 2012;119(3):373-80
   PubMed Web of Science ®Google Scholar
• Rana AQ , Vaid H , Akhter MR , et al. Prevalence of nocturia in Parkinson’s disease patients from various ethnicities. Neurol Res 2014;36(3):234-8
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R , Mekawichai P , Jitkritsadakul O , et al. Nocturnal journey of body and mind in Parkinson’s disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. J Neural Transm 2014;121(Suppl 1):S59-68
   PubMed Web of Science ®Google Scholar
• Storch A , Schneider CB , Wolz M , et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80(9):800-9
   PubMed Web of Science ®Google Scholar
• Stacy M , Hauser R . Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease. J Neural Transm 2007;114(2):211-17
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P , Hernandez B . The Q10 questionnaire for detection of wearing-off phenomena in Parkinson’s disease. Parkinsonism Relat Disord 2012;18(4):382-5
   PubMed Web of Science ®Google Scholar
• Kondo T , Takahashi K . Translation and linguistic validation of the Japanese version of the wearing-off questionnaires(WOQ-19 and WOQ-9). Brain Nerve 2011;63(11):1285-92
   PubMedGoogle Scholar
• Chan A , Cheung YF , Yeung MA , et al. A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson’s disease. Clin Neurol Neurosurg 2011;113(7):538-40
   PubMed Web of Science ®Google Scholar
• Hauser RA , Friedlander J , Zesiewicz TA , et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23(2):75-81
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R , Truong DD . Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 2008;266(1-2):204-15
   PubMed Web of Science ®Google Scholar
• Olanow CW , Fahn S , Muenter M , et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994;9(1):40-7
   PubMed Web of Science ®Google Scholar
• Lieberman A . Efficacy and safety of pramipexole in advanced Parkinson’s disease patients with the "wearing-off" phenomenon. Neurology 1996;46:A475
   Google Scholar
• Lieberman A , Olanow CW , Sethi K , et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 1998;51(4):1057-62
   PubMed Web of Science ®Google Scholar
• Lieberman A , Ranhosky A , Korts D . Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-8
   PubMed Web of Science ®Google Scholar
• LeWitt PA , Lyons KE , Pahwa R . Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68(16):1262-7
   PubMed Web of Science ®Google Scholar
• Destee A , Schneider E , Gershanik O , et al. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (not on treatment with DA-agents). Mov Disord 1996;11(suppl 1):269
   Google Scholar
• Mizuno Y , Abe T , Hasegawa K , et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG study. Mov Disord 2007;22(13):1860-5
   PubMed Web of Science ®Google Scholar
• Schapira AH , Barone P , Hauser RA , et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011;77(8):767-74
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R , Ling H . Treatment of Parkinson’s disease in Thailand: review of the literature and practical recommendations. J Med Assoc Thai 2009;92(1):142-54
   PubMedGoogle Scholar
• Antonini A , Tolosa E , Mizuno Y , et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 2009;8(10):929-37
   PubMed Web of Science ®Google Scholar
• Zhang Z , Wang J , Zhang X , et al. An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson’s disease. Curr Med Res Opin 2015;1-8
   PubMedGoogle Scholar
• Zhou CQ , Zhang JW , Wang M , Peng GG . Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson’s disease. J Clin Neurosci 2014;21(7):1094-101
   PubMed Web of Science ®Google Scholar
• Zhang Z , Wang J , Zhang X , et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord 2013;19(11):1022-6
   PubMed Web of Science ®Google Scholar
• Takanashi M , Shimo Y , Hatano T , et al. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson’s disease: results from an open-label study. Drug Res (Stuttg) 2013;63(12):639-43
   PubMedGoogle Scholar
• Mizuno Y , Yamamoto M , Kuno S , et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol 2012;35(4):174-81
   PubMed Web of Science ®Google Scholar
• Yun JY , Kim HJ , Lee JY , et al. Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson’s disease. BMC Neurol 2013;13:113
   PubMed Web of Science ®Google Scholar
• Mizuno Y , Kanazawa I , Kuno S , et al. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 2007;22(1):75-80
   PubMed Web of Science ®Google Scholar
• Ahn TB , Im JH , Lee MC , et al. One-year open-label study of entacapone in patients with advanced Parkinson disease. J Clin Neurol 2007;3(2):82-5
   PubMed Web of Science ®Google Scholar
• Lee MS , Kim HS , Cho EK , et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease. Neurology 2002;58(4):564-7
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group . A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Rascol O , Brooks DJ , Melamed E , et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• European medicines agency. Available from: http://www.ema.europa.eu/ema/
   Google Scholar
• Murata M . Zonisamide: a new drug for Parkinson’s disease. Drugs Today (Barc) 2010;46(4):251-8
   PubMed Web of Science ®Google Scholar
• Guttman M . Efficacy of istradefylline in Parkinson’s diease patients treated with levodopa with motor response complications: results of the KW-6002 US-018 study. Mov Disord 2006;21(Suppl 15):S585
   PubMed Web of Science ®Google Scholar
• Hauser R , Shulman LM , Trugman JM , et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 2008;23(15):2177-85
   PubMed Web of Science ®Google Scholar
• Hauser RA , Hubble JP , Truong DD . Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61(3):297-303
   PubMed Web of Science ®Google Scholar
• Mizuno Y , Hasegawa K , Kondo T , Japanese Istradefylline Study G . Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 2010;25(10):1437-43
   PubMed Web of Science ®Google Scholar
• Clarke CE , Worth P , Grosset D , Stewart D . Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord 2009;15(10):728-41
   PubMed Web of Science ®Google Scholar
• Swope DM . Rapid treatment of “wearing off” in Parkinson’s disease. Neurology 2004;62(6 Suppl 4):S27-31
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R , LeWitt P , Martin A , et al. Effective Delivery of Apomorphine in the Management of Parkinson’s Disease: Practical Considerations for Clinicians and Parkinson’s Nurses. Clin Neuropharmacol 2015;38(3):89-103
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr , Hutton JT , LeWitt PA , Factor SA . A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58(9):1385-92
   PubMed Web of Science ®Google Scholar
• Pahwa R , Koller WC , Trosch RM , Sherry JH . Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258(1-2):137-43
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF , Gutmann L , Hull KL , Investigators APOS . Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 2007;13(2):93-100
   PubMed Web of Science ®Google Scholar
• Poewe W , Lees A , Chaudhuri KR , Isaacson S . New perspectives in non-oral drug delivery in Parkinson’s disease. European Neurological Review 2014;9(1):31-6
   Google Scholar
• Martinez-Martin P , Reddy P , Katzenschlager R , et al. EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson’s Disease. Mov Disord 2014;30(4):510-16
   PubMed Web of Science ®Google Scholar
• Wenzel K , Homann CN , Fabbrini G , Colosimo C . The role of subcutaneous infusion of apomorphine in Parkinson’s disease. Expert Rev Neurother 2014;14(7):833-43
   PubMed Web of Science ®Google Scholar
• Poewe W , Antonini A . Novel formulations and modes of delivery of levodopa. Mov Disord 2015;30(1):114-20
   PubMed Web of Science ®Google Scholar
• Antonini A , Isaias IU , Canesi M , et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22(8):1145-9
   PubMed Web of Science ®Google Scholar
• Fernandez HH , Vanagunas A , Odin P , et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat Disord 2013;19(3):339-45
   PubMed Web of Science ®Google Scholar
• Olanow CW , Kieburtz K , Odin P , et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13(2):141-9
   PubMed Web of Science ®Google Scholar
• Merola A , Rizzi L , Zibetti M , et al. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson’s disease: a different long-term outcome? J Neurol Neurosurg Psychiatry 2014;85(5):552-9
   PubMed Web of Science ®Google Scholar
• Chan AY , Yeung JH , Mok VC , et al. Subthalamic nucleus deep brain stimulation for Parkinson’s disease: evidence for effectiveness and limitations from 12 years’ experience. Hong Kong Med J 2014;20(6):474-80
   PubMed Web of Science ®Google Scholar
• Bronstein JM , Tagliati M , Alterman RL , et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68(2):165
   PubMed Web of Science ®Google Scholar
• Singapore ministry of health. Clinical practice guidelines: Parkinson’s disease 2007
   Google Scholar
• Malaysian movement disorders council. 2012 Consensus guidelines for the treatment of Parkinson’s disease 2012
   Google Scholar
• Bhidayasiri R . Clinical practice guidelines for diagnosis and management of parkinson’s disease. Chulalongkorn center of excellence on parkinson’s disease & related disorders: Bangkok, Thailand, 2012
   Google Scholar
• Koller W , Vetere-Overfield B , Gray C , et al. Environmental risk factors in Parkinson’s disease. Neurology 1990;40(8):1218-21
   PubMed Web of Science ®Google Scholar
• Palacios C , Gonzalez L . Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2014;144 Pt A:138-45
   PubMed Web of Science ®Google Scholar
• DeLuca GC , Kimball SM , Kolasinski J , et al. Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 2013;39(5):458-84
   PubMed Web of Science ®Google Scholar
• Benamer HT , de Silva R , Siddiqui KA , Grosset DG . Parkinson’s disease in Arabs: a systematic review. Mov Disord 2008;23(9):1205-10
   PubMed Web of Science ®Google Scholar